{"classes":[{"categories":[{"measurements":[{"comment":"The median estimates of time to event, upper and lower limits of 95% CI were not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The upper limit of 95% CI was not estimable due to the small number of events.","groupId":"OG001","lowerLimit":"6.5","upperLimit":"NA","value":"11.1"},{"comment":"The upper limit of 95% CI was not estimable due to the small number of events.","groupId":"OG002","lowerLimit":"9.2","upperLimit":"NA","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"},{"groupId":"OG001","value":"188"},{"groupId":"OG002","value":"190"}],"units":"Participants"}],"description":"The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Ovarian Cancer 28 (EORTC QLQ-OV28) is a 28 item instrument with 7 functional domain subscales. Time to deterioration was defined as the time from randomization to the first time the participant's score showed a 15-point or higher increase in the score of the abdominal/GI symptom subscale of the EORTC QLQ-OV28.","dispersionType":"95% Confidence Interval","groups":[{"description":"Avelumab 10 milligram (mg)/kilogram (kg) given as a 1-hour intravenous (IV) infusion every 2 weeks (Q2W) in 4-week cycles.","id":"OG000","title":"Avelumab"},{"description":"Avelumab 10 mg/kg given as a 1-hour IV Q2W in 4-week cycles + pegylated liposomal doxorubicin (PLD) 40 mg/square meter given as a 1-hour IV infusion every 4 weeks (Q4W) in 4-week cycles.","id":"OG001","title":"Avelumab + PLD"},{"description":"PLD 40 mg/square meter given as a 1-hour IV infusion Q4W in 4-week cycles.","id":"OG002","title":"Pegylated Liposomal Doxorubicin (PLD)"}],"paramType":"MEDIAN","populationDescription":"The analysis is based on the FAS. The FAS included all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From Day 1 of Cycle 1 to prior to end of treatment/withdrawal visit, based on cutoff date: 19 September 2018.","title":"Time to Deterioration in Abdominal/GI Symptom Subscale of EORTC QLQ-OV28","type":"SECONDARY","unitOfMeasure":"months"}